

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
24 December 2003 (24.12.2003)

PCT

(10) International Publication Number  
**WO 03/105766 A2**

(51) International Patent Classification<sup>7</sup>: **A61K**

(21) International Application Number: **PCT/US03/18734**

(22) International Filing Date: 12 June 2003 (12.06.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
60/388,006 12 June 2002 (12.06.2002) US  
60/449,553 24 February 2003 (24.02.2003) US

(71) Applicant (for all designated States except US): **UNIVERSITY OF VIRGINIA PATENT FOUNDATION**  
[US/US]; 1224 West Main Street, Suite 1-110, Charlottesville, VA 22903 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **SMITH, Jeffrey, A.**


[US/US]; 815 Stillwater Lane, Earlysville, VA 22936 (US).  
**LANNIGAN-MACARA, Deborah, A.** [CA/US]; 1700 Jefferson Park Avenue, Charlottesville, VA 22903 (US).  
**POTEET-SMITH, Celeste, E.** [US/US]; 815 Stillwater Lane, Earlysville, VA 22936 (US). **HECHT, Sidney, M.** [US/US]; 4710 Dickerson Road, Charlottesville, VA 22911 (US). **XU, Yaming** [CN/US]; 406 Farrish Circle, Apt. 1, Charlottesville, VA 22903 (US). **BRAUTIGAN, David, L.** [US/US]; 1665 Blackwood Road, Charlottesville, VA 22901 (US).

(74) Agent: **BREEN, John, P.**; University of Virginia Patent Foundation, 1224 West Main Street, Suite 1-110, Charlottesville, VA 22903 (US).


(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,

*[Continued on next page]*

(54) Title: RSK INHIBITORS AND THERAPEUTIC USES THEREOF




SL0101-1



SL0101-2

(57) Abstract: The present invention is directed to novel compounds and compositions that have Rsk specific inhibitory activity. In addition, inhibition of Rsk by the present compounds has been discovered to halt the proliferation of cancer cell lines while having little effect on the proliferation rate of normal cells. Therefore, the present invention identifies Rsk as a target for therapeutic intervention in diseased states in which the disease or the symptoms can be ameliorated by inhibition of Rsk catalytic activity.



SL0101-3